Strategy
MSTR
Coinbase
COIN
Alphabet-A
GOOGL
Alphabet-C
GOOG
Meritage Homes
MTH
US Stock MarketDetailed Quotes
VERV Verve Therapeutics
- 6.120
- -0.050-0.81%
Close Mar 4 16:00 ET
- 6.170
- +0.050+0.82%
Post 20:01 ET
543.43MMarket Cap-2.60P/E (TTM)
6.170High5.680Low1.50MVolume5.860Open6.170Pre Close8.89MTurnover2.30%Turnover RatioLossP/E (Static)88.80MShares15.55052wk High1.10P/B397.98MFloat Cap4.30552wk Low--Dividend TTM65.03MShs Float78.000Historical High--Div YieldTTM7.94%Amplitude4.305Historical Low5.932Avg Price1Lot Size
About Verve Therapeutics Company
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Company Profile
SymbolVERV
Company NameVerve Therapeutics
Listing DateJun 17, 2021
Issue Price19.00
Founded2018
CEODr. Sekar Kathiresan, M.D.
MarketNASDAQ
Employees274
Fiscal Year Ends12-31
Address201 Brookline Avenue,Suite 601
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02215
Phone1-617-603-0070
Websitehttp://www.vervetx.com
Company Executives
- Name
- Position
- Salary
- Dr. Sekar Kathiresan, M.D.
- Chief Executive Officer and Director
- 9.32M
- Andrew D. Ashe, J.D.
- President and Chief Operating Officer
- --
- Joan Nickerson
- Chief Administrative Officer
- --
- Frederick Fiedorek, M.D.
- Chief Medical Officer
- --
- Troy Lister, PhD
- Chief Scientific Officer
- --
- Dr. Ourania Tatsis, PhD
- Director; Executive Vice President and Chief Regulatory and Quality Officer of Vertex Pharmaceuticals
- --
- Allison Dorval
- Chief Financial Officer and Principal Accounting Officer
- 3.48M
- Dr. Burt A. Adelman, M.D.
- Chairman of the Board
- 451.88K
- Jodie P. Morrison
- Independent Director
- --
- Dr. Krishna Yeshwant, M.D.
- Independent Director
- 410.88K
- Michael F. Maclean
- Independent Director
- 521.07K
- Sheila Mikhail, J.D.
- Independent Director
- 412.38K
- Alexander G. Cumbo
- Independent Director
- 405.88K
- Lonnel Coats
- Independent Director
- 407.38K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.